skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
70-Gene Signature in Early-Stage Breast Cancer — NEJM
The authors reply:
.....We agree that evaluating health-related quality of life is extremely
important. However, patients in our study could potentially have been
asked to sign four informed-consent documents, depending on their group
assignment, and all the study patients had to comprehend the
complexities of the trial, including information on genomic testing. We
decided that the addition of quality-of-life questionnaires to the
overall study would be too burdensome for the patients, a decision that
was supported by patient advocates. At the time of the study, there
existed no validated instrument to evaluate the psychological effects of
genomic testing on patients, although we agree that such evaluation is
important.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.